Gralise FDA Approval History
FDA Approved: Yes (First approved January 28, 2011)
Brand name: Gralise
Generic name: gabapentin
Dosage form: Extended Release Tablets
Previous Name: DM-1796
Company: Depomed, Inc.
Treatment for: Postherpetic Neuralgia
Gralise (gabapentin) is an extended release, tablet formulation of the approved antiepileptic agent gabapentin, indicated for the once-daily treatment of post-herpetic neuralgia (PHN).
Development timeline for Gralise
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.